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staging in high-risk prostate cancer patients and its
influence on disease management -
a retrospective study
Sara Strandberg*, Camilla Thellenberg Karlsson, Torbjörn Sundström, Mattias Ögren, Margareta Ögren,
Jan Axelsson and Katrine RiklundAbstract
Background: Radiation treatment with simultaneous integrated boost against suspected lymph node metastases
may be a curative therapeutic option in patients with high-risk prostate cancer (>15% estimated risk of pelvic lymph
node metastases according to the Cagiannos nomogram). 11C-acetate positron emission tomography/computed
tomography (PET/CT) can be used for primary staging as well as for detection of suspected relapse of prostate
cancer. The aims of this study were to evaluate the association between positive 11C-acetate PET/CT findings and
the estimated risk of pelvic lymph node metastases and to assess the impact of 11C-acetate PET/CT on patient
management in high-risk prostate cancer patients.
Methods: Fifty consecutive prostate cancer patients referred for primary staging with 11C-acetate PET/CT prior to
radiotherapy with curative intention were enrolled in this retrospective study.
Results: All patients showed increased 11C-acetate uptake in the prostate. Pelvic lymph node uptake was seen in
42% (21/50) of the patients, with positive external iliac lymph nodes in 71% (15/21) of these. The overall observed
proportion of PET/CT-positive pelvic lymph nodes at patient level was higher than the average estimated risk, especially
in low-risk groups (<15%). There was a significant association between observed proportion and estimated risk of pelvic
lymph node metastases in groups with ≤45 and >45% estimated risk. Treatment strategy was altered due to 11C-acetate
PET/CT findings in 43% (20/47) of the patients.
Conclusions: The observed proportion of 11C-acetate PET/CT findings suggestive of locoregional metastases was higher
than the estimated risk, suggesting that the Cagiannos nomogram underestimates the risk for metastases. The imaging
results with 11C-acetate PET/CT have a considerable impact on patient management.
Keywords: Prostatic neoplasms; PET/CT; 11C-acetate; Neoplasm staging; Lymphatic metastasisBackground
During a lifetime, approximately 15% of men will be
diagnosed with prostate cancer, making it the second most
common cancer form in males worldwide [1]. According
to the Swedish National Prostate Cancer Registry, it is the
most common cancer in males in Sweden, with an
incidence of approximately 10,000 and a mortality of 2,500
annually [2]. Prostate cancer is a complex heterogeneous
disease with highly variable morphological and physiological* Correspondence: sara.strandberg@vll.se
Department of Radiation Sciences, Umeå University, 90185, Umeå, Sweden
© 2014 Strandberg et al.; licensee Springer. Thi
Commons Attribution License (http://creativeco
reproduction in any medium, provided the origcharacteristics [3]. Staging and risk categorisation is decided
from clinical features including T stage, prostate-specific
antigen (PSA) and Gleason score. Risk estimation can
be facilitated with the use of nomograms such as the
Cagiannos nomogram, which is a widely used clinical
tool to determine the extent of disease as well as the
risk of pelvic lymph node involvement [4]. Prostate
cancer with >15% estimated risk of pelvic lymph node
metastases is considered as high-risk prostate cancer
but still stands a chance to get cured with standard
radiotherapy including the prostate and the seminals is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
Table 1 Patient characteristics
n Mean Range
Patients (n) 50
Age (years) 67 41 to 77
PSA (ng/ml) 37 2.7 to 168
Gleason score 8 6 to 10
Estimated risk of locoregional lymph
node metastases (%)a
32 3.3 to 80.3
aAccording to the Cagiannos pre-treatment nomogram, where age, pre-treatment
PSA, clinical tumour stage, primary and secondary Gleason grade, and the number
of positive and negative biopsy cores influence the estimated risk.
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approach including the pelvic lymph nodes is under
development [5] and is used in the treatment of high-risk
prostate cancer in the University Hospital of Umeå.
Nomograms will only provide an estimated risk of pelvic
lymph node metastasis, and it is necessary to establish a
more reliable non-invasive method for staging. Hybrid
imaging with positron emission tomography/computed
tomography (PET/CT) renders various molecular and
morphological information, depending on the radiotracer
and the design of the CT protocol. PET/CT is widely used
in oncologic imaging for cancer staging and restaging as
well as for evaluation of treatment response. The most
used radiotracer 18F-FDG (2-deoxy-2-[18F]-D-glucose) is
an indicator of glucose metabolism, which has proved
useful in several malignant tumours due to their increased
glycolysis, the Warburg effect [6], but it has limitations
in relatively slow-growing malignancies such as prostate
cancer. For PET/CT imaging in prostate cancer, 11C-acetate,
11C-choline, and 18F-choline appear to be more suitable
tracers [7]. Multiple other promising new tracers are under
development for imaging in prostate cancer but still need
further investigation [8,9]. Currently, 11C-/18F-choline
and 11C-acetate are the most commonly used tracers,
with comparable results [7,10]. A recent study by
Buchegger et al. showed excellent concordance between
18F-choline and 11C-acetate in the detection and localization
of positive lymph nodes and skeletal metastases in patients
with prostate cancer [10]. 11C-choline-PET/CT has proved
valuable mainly for radiotherapy planning in prostate
cancer patients with biochemical recurrence after radical
treatment [11]. 11C-acetate is a radiotracer that is believed
to reflect lipid metabolism, but its exact pharmacodynamic
mechanism is still debated [12]. Several studies indicate
that 11C-acetate is of value for primary staging of prostate
cancer [8,13-15]. Oyama et al. have shown 11C-acetate to
be superior to 18F-FDG with higher sensitivity for prostate
cancer and its metastases [13]. In 2012, Castellucci and
Jadvar suggested in a review of PET/CT in prostate cancer
that the main application for 11C-acetate might be to rule
out distant metastases in early prostate cancer relapse prior
to salvage radiotherapy [8].
The aims of this retrospective study were to evaluate the
correlation between 11C-acetate PET/CT findings and the
estimated risk of locoregional lymph node metastases as
indicated by the Cagiannos nomogram and to assess the
impact of 11C-acetate PET/CT examination results on the
clinical management of previously untreated high-risk
prostate cancer patients.
Methods
Patients and clinical data
Fifty consecutive patients referred for 11C-acetate PET/CT
at Nuclear Medicine, Department of Radiology, UniversityHospital of Umeå, Sweden, from 2011 July 6 to 2013
March 26 were included. The cause for referral was
primary staging of biopsy-verified prostate cancer prior
to radiotherapy with curative intention. Patients were
referred for 11C-acetate PET/CT if they reached 15% risk
in the nomogram or if they exhibited other risk factors
such as rapidly increasing PSA. The time interval between
biopsy and 11C-acetate PET/CT was at an average of 8
weeks, range 3 to 18 weeks. All patients had a baseline
11C-acetate PET/CT scan, of which 90% (45/50) had a
contrast-enhanced CT (CECT) scan in the same session.
The remaining five patients had a diagnostic CT scan
without intravenous (i.v.) contrast due to either impaired
renal function or a previous examination with i.v. iodine
contrast media within 4 weeks.
Clinical information regarding pre-treatment status
was retrieved from the referral text. Follow-up data were
collected from the patients' medical records. Clinical data
concerning changes in treatment strategy were missing in
three patients referred from regional hospitals, and these
patients were excluded from the evaluation of impact
of 11C-acetate PET/CT findings on treatment strategy. The
study was approved by the regional ethics review board.
The Cagiannos pre-treatment nomogram was used to
estimate the risk of pelvic lymph node involvement.
Factors taken into account in the nomogram are age,
pre-treatment PSA, clinical tumour stage, primary and
secondary Gleason grade, and the number of positive
and negative biopsy cores [16]. Estimated risk data
could be calculated for all patients except one, where
clinical data were missing. This patient was excluded from
the evaluation of the correlation between 11C-acetate
PET/CT findings and the estimated risk of locoregional
lymph node metastases. Patient characteristics are shown
in detail in Table 1.
PET/CT imaging
All image acquisition was done with a GE Discovery 690
PET/CT scanner (General Electric, Pewaukee, WI, USA).
Software and algorithms were supplied with the scanner.
The patients were injected with 1-[11C]-acetate (5.0 MBq/kg
body weight, mean dose 436 MBq, range 304 to 577 MBq)
Table 2 Criteria for low, intermediate, and high grade of
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acquired, followed by a PET scan 10 min post-injection and
finally a diagnostic CT with or without i.v. contrast media.
The attenuation CT was a helical 0.5-s rotation time scan,
employing 120 kV and 30 mA. The PET scan was
performed in time-of-flight mode with an acquisition
time of 2 min/bed position, including the abdomen,
thorax and neck. The PET images were reconstructed
with the OSEM-based VuePoint HD (GE Healthcare,
Pewaukee, WI, USA) (2 iterations, 24 subsets, 6.4 mm
Gaussian filter), to a 128 × 128 pixel matrix with 50-cm
field-of-view, giving a voxel size of 5.5 × 5.5 × 3.27 mm3.
The diagnostic CT included the neck, thorax and
abdomen, using 120 kV, with beam current controlled
by the Auto-mA algorithm (noise index 35, current
limited to the range 150 to 750 mA). The CECT was done
after i.v. injection of iodine contrast (Omnipaque
350 mgI/ml 0.5 g I/kg, rendering a patient mean volume
of 137 ml, range 108 to 167 ml).
Evaluation of image data
Two physicians double licensed in radiology and nuclear
medicine (one with >10 years' experience from reading
PET/CT and one with 2 years' experience) visually
evaluated all PET/CT studies. Any exceptional cases
of inter-observer disagreement were solved with consensus.
The radiologists had access to basic clinical data available
in the referral text, typically length of disease, Gleason score
and PSA levels. Lesions with acetate uptake visually
exceeding the background activity were considered positive.
The uptakes were quantified by measurements of the
highest standardised uptake value - maximum pixel
activity in correlation to body weight and the injected
dose, grams per millilitre (standardised uptake value
(SUVmax)). All visually positive uptakes were measured in
box regions of interest (ROIs) with PET VCAR software
(AW 4.5, General Electric, Pewaukee, WI, USA) to deter-
mine SUVmax. The mediastinal background was measured
in reference ROIs. The ROIs were delineated with a
threshold of 42% of maximum signal intensity [17,18].
The morphological criteria for suspected lymph node
metastases were round shape, short-axis diameter exceeding
10 mm, lack of fat-containing hilus and visually increased
contrast enhancement compared to normal lymph nodes.
Other suspected metastatic sites were skeletal and hepatic
lesions. The morphological criteria for suspected bone
metastasis on CT were sclerotic, lytic or mixed lesions
with destruction of cortical bone. Characteristics consistent
with suspected hepatic metastases on CT were hypo- or
hyperattenuating hepatic masses with irregular delineation
and/or pathologic pattern of contrast enhancement.
The distinction between low, intermediate and high
grade of suspicion of lymph node metastasis was based on
the combination of the level of SUVmax, morphologicalchanges in size and structure and pathological contrast
enhancement, according to generally defined and accepted
criteria for evaluation of lymph node involvement in CT as
well as in 18F-FDG PET studies. Low-grade suspicious
lesions have been considered non-metastatic. Intermediate-
and high-grade suspicious lesions have been evaluated as
metastatic. The systematic interpretation of lymph nodes is
described in detail in Tables 2 and 3. Depending on the
level of SUVmax, also normal-appearing lymph nodes can
be categorised as intermediate grade, and vice versa,
morphologically aberrant lymph nodes with just a slight
increase in SUVmax are categorised as high grade according
to Tables 2 and 3. The high grade of suspicion requires
both PET and CT changes, whereas in the intermediate
group, the level of the SUVmax is the critical parameter.
Pelvic locoregional lymph nodes and distant paraaortal
lymph nodes were evaluated with slightly different criteria
than other distant lymph nodes regarding the impact of the
level of SUVmax, in order to reduce the number of
false-positive reactive lymph nodes in the thorax and
the inguinal regions, where prostate cancer metastases
are less likely to occur (Tables 2 and 3). Paraaortal
lymph node metastases per definition are considered
distant metastases. Our division of lymph nodes into
pelvic and paraaortal versus other distant lymph node
metastases was due to anatomical reasons - the
lymphatic drainage from the prostate makes it more likely
to find metastases in the pelvic and paraaortal lymph
nodes. Also, low-grade uptake in small mediastinal lymph
nodes is a relatively common finding of unclear clinical
significance, making these lymph nodes more difficult to
interpret. The paraaortal lymph nodes were thus treated
with higher degree of suspicion than other distant sites,
with regard to likelihood of metastasis.
Statistical analysis
Different risk groups regarding the estimated risk of
locoregional lymph node metastases versus the observed
risk were compared with Pearson's chi-square test. The
association between prostate SUVmax, PSA and Gleason
score, respectively, and the presence of metastatic disease
was evaluated with binary logistic regression analysis.
Table 3 Criteria for low, intermediate, and high grade of
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score were evaluated using linear regression analysis. For
more reliable sample sizes, patients were merged into three
Gleason score groups: Gleason score 6 to 7, 8 and 9 to 10.
The chosen significance level was p <0.05. All statistical
analyses were executed in IBM SPSS Statistics 21
(SPSS Inc., Chicago, IL, USA).
Results
Distribution of positive 11C-acetate PET/CT findings
All patients showed increased heterogeneous acetate
uptake of the prostate (mean SUVmax 7.3 g/ml, range
3.3 to 13.8 g/ml); typical appearance is shown in Figure 1.
Suspected lymph node metastases were seen in 105 lymph
nodes in 42% (21/50) of the patients, most frequently
along the external iliac vessels, which was the case in 71%
(15/21) of the patients (typical uptake shown in Figure 2).
In 45% (47/105) of the positive lymph nodes, only PET
was positive, and in the other 55% (58/105), both PET and
CT were pathologic. Distribution and characteristics of
suspected locoregional lymph node metastases are shown
in detail in Table 4.Figure 1 Increased acetate uptake (SUVmax 9.6) of the prostate in patPreviously unknown distant metastases were found in
28% (14/50) of patients: located in paraaortal lymph nodes
in six patients, mediastinal lymph nodes in eight and
cervical lymph nodes in one patient (example shown in
Figure 3). Among the 14 patients with suspected
distant metastases were four with skeletal metastases.
Unexpected incidental findings in two patients were
biopsy-verified synchronous renal cell carcinoma and
hepatocellular carcinoma. Distribution of suspected
distant metastases and incidental findings are shown
in detail in Table 5.
Low-grade mediastinal lymph node uptake (SUVmax
range 2.3 to 5.8 g/ml) with low suspicion of lymph node
metastasis was seen in 22% (11/50) of the patients
with 22 nodal uptakes in total. In 55% (6/11) of these
patients, only non-specific mediastinal lymph node
uptake was seen and 45% (5/11) of the patients had both
non-specific and suspected metastatic mediastinal lymph
node uptakes.
Association between 11C-acetate PET/CT findings and the
estimated risk of locoregional lymph node metastases
Patients were divided into three groups according to
estimated risk of pelvic lymph node metastases, <15%
(n = 12), 15 to 45% (n =24) and >45% (n = 13),
respectively. The observed proportions of pelvic
lymph node metastases in the three groups were 33,
33 and 69%, respectively. The Pearson chi-square test
displayed that there was no significant association
between the observed proportion and the estimated
nomogram risk of pelvic lymph node metastases in
the three original groups (p = 0.08). Merging the first
and the second groups, those with ≤45% estimated
risk had positive pelvic lymph nodes in 33% (12/36),
and those with >45% risk had positive pelvic lymphient with prostate cancer.
Figure 2 Increased acetate uptake in suspected iliac lymph node metastasis in a prostate cancer patient.
Strandberg et al. EJNMMI Research 2014, 4:55 Page 5 of 9
http://www.ejnmmires.com/content/4/1/55nodes in 69% (9/13), and this association proved to
be significant (p <0.05).
The overall estimated mean risk of pelvic lymph node
metastases was 32%, while the observed proportion of sus-
pected pelvic lymph node metastases was 43% (21/49).
Twelve patients had an estimated risk <15%. All of
these patients had 11C-acetate-positive lesions in the
prostate and 3/12 patients (25%) showed suspected
pelvic lymph node involvement, two with intermediate
and one with high suspicion of metastasis.Prognostic value of prostate SUVmax
Binary logistic regression analysis proved prostate SUVmax
to be higher in patients with suspected pelvic lymph node
spread (odds ratio (OR) 1.45, p <0.05). Neither prostate
SUVmax, PSA or Gleason score was associated with the
presence of suspected distant metastases, nor were PSA or
Gleason score associated with suspected pelvic lymph
node spread.
There was a significant positive correlation between pros-
tate SUVmax and PSA (Pearson correlation coefficient 0.35,
p <0.05), but not with Gleason score. PSA and Gleason




High-grade suspicious LN metastases
(mean SUVmax g/ml and mean short axis mm)
In
m
Pararectal 6 (5.4 g/ml, 20 mm) 0
Obturator 6 (5.2 g/ml, 9.7 mm) 2 (
External iliac 28 (6.6 g/ml, 14 mm) 36
Internal iliac 11 (6.5 g/ml, 14 mm) 4 (
Common iliac 7 (4.8 g/ml, 13 mm) 5 (
∑ 58 47
a21 patients with acetate uptakes in multiple locations.Impact of 11C-acetate PET/CT findings on treatment
strategy
In 43% (20/47) of the patients, treatment strategy was
altered due to 11C-acetate PET/CT findings (Table 6).
Eleven of these had an estimated risk of pelvic lymph
node metastases ≤45% and the remaining nine >45%,
with treatment changes as indicated in Table 7. In 19%
(9/47) of the patients, suspected pelvic lymph node
metastases (SUVmax 2.6 to 11.0 g/ml, short axis 5 to 16
mm) were treated with additional radiotherapy boost
(mean additional dose 17 Gy, range 15 to 26 Gy). The
nine patients that received additional radiotherapy boost
against suspected pelvic lymph node metastases were
fully informed of the non-conventional approach in this
treatment, and all chose to go forward with it. The
selected lymph nodes were irradiated according to the
proposed Radiotherapy Oncology Group (RTOG) lymph
node template. Lymph nodes were only boosted if
they were within this field. Otherwise, the patients were
considered to have distant metastases. The disease was far
more extensive than expected, and therapeutic options
were no longer curative in 21% (11/47) of the patients. The
findings were confirmed with conventional examinations
such as bone scintigraphy, and occasionally with biopsy,h-grade suspicious locoregional lymph node uptakes,
termediate suspicious LN






2.9 g/ml) 6 8
(3.9 g/ml) 15 64
4.7 g/ml) 9 15
4.3 g/ml) 6 12
21a 105
Figure 3 Increased acetate uptake in pathologically enlarged paraaortal lymph nodes in patient with prostate cancer.
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non-curative. Patients that were switched to palliative
treatment received androgen deprivation therapy except
for one patient who declined because of a diagnosis of
previously unknown synchronous hepatocellular carcin-
oma accidentally detected on 11C-acetate PET/CT. Three
out of the eleven patients also got radiotherapy to the
prostate to palliate local symptoms. In 1/11 patients,
radiotherapy treatment was cancelled due to comorbidity.
The remaining 57% (27/47) were treated with standard
radiotherapy as initially planned. Standard radiotherapy
of the prostate gland did not change due to 11C-acetate
















Axillary LN 1 (SUVmax 9.0 g/ml) 1 (short axis
10 mm)
Roun
Cervical LN 2 (mean SUVmax 5.6 g/ml) 2 (mean short
axis 10 mm)
Roun
Skeletal 20 (mean SUVmax 7.1 g/ml) 20 Sclero
Liver 1 (SUVmax 14.3 g/ml) 1 Hypo
mass
Kidney 1 (SUVmax 14.2 g/ml) 1 Heter
mass
∑ 39 39
aSix patients with multiple sites, in total 14 with suspected distant metastases, and
cell carcinoma.Discussion
There was a statistically significant association between
the observed proportions of 11C-acetate PET/CT findings
suggestive of pelvic lymph node metastases in merged
estimated risk groups ≤45 and >45% according to the
established Cagiannos nomogram, which supports the
value of 11C-acetate PET/CT in pelvic lymph node
staging of primary prostate cancer. The lack of a sta-
tistically significant result in the original three risk
groups can be explained by inadequate power of the
study since the number of patients in each risk group
is low. Surprisingly, patients with previously estimated







rounded 6 6 (4 solitary, 2
conglomerates)
rounded 8 8 (6 solitary, 2
conglomerates)
ded shape 1 1
ded shape 1 2 (2 conglomerates)
tic 4 20
attenuating HCC 1 -
ogeneous RCC 1 -
22a 37
two with incidental findings. HCC, hepatocellular carcinoma; RCC, renal
Table 6 11C-acetate PET/CT findings resulting in altered treatment strategy










1 Iliac int/ext Paraaortal LN - - Palliative RT
2 Iliac ext Skeletal - - No RT
3 Iliac int/ext - - RT boost 16 Gy -
4 Iliac int/ext - RT boost 16 Gy -
5 Iliac ext - - RT boost 16 Gy -
6 Iliac com - RT boost 16 Gy -
7 Iliac int/ext - - RT boost 16 Gy -
8 Obt, iliac int/ext/com - RT boost 15 Gy -
9 - - HCC with paraaortal LN - No RT
10 Iliac ext - RT boost 20 Gy -
11 Obt, iliac int/ext/com Paraaortal LN, skeletal - - No RT
12 Pararectal, iliac ext - - RT boost 26 Gy -
13 Pararectal, obt, iliac int/ext/com Paraaortal LN - - Palliative RT
14 Iliac int/ext/com Paraaortal, thoracic, cervical LN - - No RT
15 - Skeletal - - No RT
16 Iliac ext - - RT boost 16 Gy -
17 Iliac ext Skeletal - - No RT
18 - - Aortic aneurysm - No RT
19 Pararectal, iliac int/ext/com Paraaortal, thoracic LN - - No RT
20 Pararectal, obt, iliac ext - - - Palliative RT
∑ 17 8 2 9 11
HCC, hepatocellular carcinoma; LN, lymph nodes; Obt, obturator; RT, radiotherapy.
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The overall observed proportion of positive PET/CT
findings suggestive of pelvic lymph node metastases
was higher than the estimated risk, suggesting either
that 11C-acetate PET/CT is superior to the clinical
prediction tool or that there is a high rate of false-positive
findings. It is possible that the inclusion criteria were such
that this resulted in higher numbers, and there may be a
selection bias especially since 11C-acetate PET/CT was a
new method at the time and is still used only in cases with
risk of pelvic lymph node involvement and where curative
radiotherapy is the intended treatment. That may explain
why our results are not comparable with other studies
based on low- and intermediate-risk groups, but it doesTable 7 Treatment change due to 11C-acetate PET/CT
findings in estimated risk groups according to Cagiannos
nomogram
Estimated risk Addition of RT
boost to pelvic LN
Change to no/palliative RT
≤45% (n =11) 4 7
>45% (n =9) 5 4
LN, lymph nodes.not explain the difference in the observed proportion of
suspected pelvic lymph node metastases versus the
expected risk in the Cagiannos nomogram. Since the
patients in our study were treated with radiotherapy, there
was no possibility to obtain histopathological confirmation
of the suspected lymph node metastases. Haseebuddin
et al. have shown a sensitivity of 68% and specificity of
78% of 11C-acetate PET/CT for detecting pelvic lymph
node metastases [15], but apart from their study, little is
published on suspected lymph node metastases with this
method. Another possible explanation for the discordance
could be that the Cagiannos nomogram underestimates
the risk of lymph node metastasis, as has been previously
suggested by Walz et al. in 2012 [19]. Schiavina et al.
showed in their study on 11C-choline PET/CT in
intermediate-risk and high-risk prostate cancer that the
specificity and accuracy of PET/CT was better than that
of the Kattan and Briganti nomograms, although the
results were not statistically significant [20]. Altogether, our
conclusion is that the higher proportion of 11C-acetate-
positive pelvic lymph nodes is not merely an artefact.
The distinction between metastatic and non-metastatic
unspecific findings in this study was based on the combin-
ation of increased SUVmax, morphological changes in size
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the established variables for characterising a lesion as
benign or malignant. In prostate cancer, however, some
data indicate that pelvic lymph nodes may be enlarged
not only due to metastatic disease but also because of
associated hyperplastic or regressive alterations [21]. On
the other hand, it is also well known that normal-sized
lymph nodes can harbour metastases.
The relatively common low intense acetate uptake in
otherwise normal-appearing mediastinal lymph nodes is
considered non-specific, but the mechanism and possible
prognostic features remain unclear. The presence of
non-specific mediastinal lymph nodes did not influence
therapy, and this finding will be followed clinically.
Mediastinal lymphadenopathy in prostate cancer is
described in several case reports in the literature as a
rare symptom of advanced disease [22-24]. This needs
further evaluation, especially with the contradictory
findings from a post-mortem study on 176 cases describ-
ing a distribution of lymph node metastases from
prostate cancer to the paraaortal regions most fre-
quently, followed by the external iliac and tracheobron-
chial regions [25].
Higher prostate SUVmax correlates in our study with
the presence of suspected pelvic lymph node metastases,
in contrast to earlier studies by Kato et al. concluding
that prostate SUV measurements in dynamic 11C-acetate
PET in known normal prostate and benign prostatic
hyperplasia overlap significantly with those for known
prostate cancer [26]. The reason for this may be the
selection of mainly high-risk prostate cancer patients
in our material.
The weaknesses of this study are that two indirect
methods to predict metastatic disease in prostate cancer
patients are compared and, as before mentioned, that
the sample population is relatively small. In future
research, the need for histopathologic confirmation is
obvious, although one recent study by Haseebuddin et al.
shows that the presence of 11C-acetate PET/CT-positive
pelvic lymph nodes independently predicts treatment
failure, despite negative histopathologic findings [15].
Furthermore, there may be a risk of selection bias as
mentioned above, but also in the low-risk group
(<15%) in this material, since they have been submitted
for 11C-acetate PET/CT despite their low risk of pelvic
lymph node metastases and may have some other
characteristic in common, of which we are unaware.
11C-acetate is a relatively new tracer for prostate cancer
staging with molecular properties reflecting the pattern of
lipid metabolism. It could potentially be used for other slow
growing cancers apart from prostate cancer such as highly
differentiated hepatocellular carcinoma (HCC), renal cell
carcinoma (RCC), bladder carcinoma and brain tumours
[27,28]. In our material of 50 patients, we found onehistology-verified RCC and one HCC, thus supporting pre-
vious studies.
The impact of 11C-acetate PET/CT on treatment
strategy is high and in line with a previous report
from Kjölhede et al. where 20% of patients examined
with combined 18F-choline PET/CT and 18F-FDG
PET/CT had their treatment plans altered [29]. This
result also complies with several other studies on 18F-FDG
PET/CT in various kinds of cancer with changes in
treatment in 21 to 62% of the patients [30-32]. In our
study, patients with limited pelvic nodal disease received
integrated radiotherapy boost to the pelvic lymph nodes.
This is a strategy that has been explored and found
feasible regarding toxicity and clinical outcome [5].
Our results indicate that 11C-acetate PET/CT might
be of value in pelvic lymph node staging in previously
untreated high-risk prostate cancer patients, but these
results should be interpreted with caution especially since
the number of patients was low and histopathological
confirmation was absent. However, the prognosis in
patients with high-risk prostate cancer is poor, there is no
optional treatment, and the risk of negative side ef-
fects is low, which makes the possible benefit of
added therapy greater than the possible harm. The
reason for excluding patients from curative treatment
has been unequivocal metastatic disease taken into
account the specificity and sensitivity issue. In our
ongoing prospective study, survival as well as biochemical
response will be assessed.
Conclusions
11C-acetate PET/CT for staging of prostate cancer influ-
ences treatment strategy in a substantial way and the use of
11C-acetate PET/CT seems to be of value in clinical practice
for previously untreated high-risk patients, although the
method needs further validation. The overall observed pro-
portion of 11C-acetate PET/CT-positive pelvic lymph nodes
is higher than the estimated pre-treatment nomogram risk,
suggesting the nomogram might underestimate the risk.
Prostate SUVmax is positively correlated to the presence of
suspected pelvic lymph node metastases in 11C-acetate
PET/CT and to PSA. Further long-term studies are needed
to evaluate the impact of 11C-acetate PET/CT findings on
patient outcome and survival.
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